相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
H. A. Ghofrani et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation
L. S. Hoffmann et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension
Joachim Mittendorf et al.
CHEMMEDCHEM (2009)
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
F. Grimminger et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Marius M. Hoeper et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Nicholas W. Morrell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Updated Clinical Classification of Pulmonary Hypertension
Gerald Simonneau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pulmonary hypertension
Gorev Grubu Uyeleri et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2009)
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
R. T. Schermuly et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Molecular pathogenesis of pulmonary arterial hypertension
Marlene Rabinovitch
JOURNAL OF CLINICAL INVESTIGATION (2008)
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521:: An ascending-dose study in healthy male volunteers
Reiner Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation
Oleg V. Evgenov et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Pulmonary hypertension: current diagnosis and treatment
S. Rosenkranz
CLINICAL RESEARCH IN CARDIOLOGY (2007)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
Johannes-Peter Stasch et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension
Joy D. Cogan et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Hossein A. Ghofrani et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Reverse remodeling - paradigm shift in the treatment of pulmonary hypertension
HA Ghofrani et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2006)
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling
R Dumitrascu et al.
CIRCULATION (2006)
BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats
Philippe Deruelle et al.
BIOLOGY OF THE NEONATE (2006)
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
Oleg V. Evgenov et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reversal of experimental pulmonary hypertension by PDGF inhibition
RT Schermuly et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Imatinib for the treatment of pulmonary arterial hypertension
HA Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells
J Wharton et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
O Sitbon et al.
CIRCULATION (2005)
Efficacy and optimal dose of sildenafil in primary pulmonary hypertension
A Chockalingam et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis
VO Melichar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats
RT Schermuly et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
HA Ghofrani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
OV Evgenov et al.
CIRCULATION (2004)
Immediate and long-term hemodynamic and clinical effects of Sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy
S Bhatia et al.
MAYO CLINIC PROCEEDINGS (2003)
Regulation of nitric oxide-sensitive guanylyl cyclase
A Friebe et al.
CIRCULATION RESEARCH (2003)
Hypoxic activation of adventitial fibroblasts - Role in vascular remodeling
KR Stenmark et al.
CHEST (2002)
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
HA Ghofrani et al.
LANCET (2002)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension
SM Black et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2001)
Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain
D Giordano et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2001)
NO-independent regulatory site on soluble guanylate cyclase
JP Stasch et al.
NATURE (2001)
Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
RA Krasuski et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
分享论文
